---
title: "Dr Agarwals Eye Hospital Ltd (526783) — Share Price, Financials & Analysis"
symbol: "526783"
company: "Dr Agarwals Eye Hospital Ltd"
canonical: "https://tapetide.com/stocks/526783"
isin: "INE934C01018"
nse_symbol: "DRAGARWQ"
bse_code: "526783"
sector: "Healthcare Services"
industry: "Hospitals"
market_cap_cr: 2562.36
generated_at: "2026-09-13T19:16:01.643Z"
---

# Dr Agarwals Eye Hospital Ltd (526783)

Canonical page: https://tapetide.com/stocks/526783

## Company

- **NSE Symbol:** DRAGARWQ
- **BSE Code:** 526783
- **ISIN:** INE934C01018
- **Sector:** Healthcare Services
- **Industry:** Hospitals
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Listed Since:** 2001-08-13
- **Face Value:** ₹10
- **F&O Eligible:** No
- **Website:** dragarwal.com

## About

Dr Agarwal's Eye Hospital Ltd is a leading chain of eye hospitals with predominant presence in Tamil Nadu.[1]

## Latest Price

- **Price:** ₹5306.5
- **Change:** +0.5 (+0.01%)
- **Open:** ₹5252
- **Day High:** ₹5350.5
- **Day Low:** ₹5252
- **Previous Close:** ₹5306
- **Volume:** 976
- **As Of:** 2026-09-11T09:59:47+00:00

## Key Fundamentals

Observed at 2026-09-11T04:53:41.256015Z.

- **Market Cap:** ₹2562.36 Cr
- **Classification:** Microcap
- **P/E (reported):** 33.7
- **P/E (TTM):** 33.65
- **EPS (TTM):** ₹157.72
- **Book Value:** ₹716.56
- **Price to Book:** 7.42
- **Dividend Yield:** 0.13%
- **ROE:** 26.07%
- **ROCE:** 15.99%
- **Debt to Equity:** 0.94
- **Revenue (yearly):** ₹470.87 Cr
- **Net Income:** ₹70.14 Cr
- **EBITDA:** ₹145.31 Cr
- **52-Week High:** ₹6059.7
- **52-Week Low:** ₹4600
- **RSI (14):** 52.54

## Tapetide Score

- **Score:** 54 / 100
- **Score date:** 2026-09-04
- **Archetype:** Priced for Perfection
- **What it means:** The business scores well but the multiple leaves little room for error. The debate here is about the price, not the company; small disappointments tend to cost more at rich valuations.
- **Pillar profile:** Quality: Good · Valuation: Expensive · Momentum: Flat
- **Percentile:** 65.6 (of 4473 scored stocks)
- **Confidence:** 100%
- **Data coverage:** 100%

| Pillar | Score | Weight |
| --- | --- | --- |
| financial health | 35.19 | 9% |
| growth | 70.42 | 9% |
| momentum | 51.06 | 12% |
| ownership | 47.54 | 24% |
| quality | 77.8 | 22% |
| valuation | 42.1 | 24% |

The Tapetide Score is decision-support only, not investment advice.

## Key Insights

### Strengths

- Company has delivered good profit growth of 120% CAGR over last 5 years
- Company has a good return on equity (ROE) track record: 3 Years ROE 28.6%

### Weaknesses

- Stock is trading at 7.41 times its book value
- Company might be capitalizing the interest cost

## Growth Rates

| Metric | QoQ | 1Y | 3Y | 5Y |
| --- | --- | --- | --- | --- |
| cash flow growth | — | 5.25% | 35.71% | 178.95% |
| ebitda margin growth | 28.05% | -0.81% | 2.94% | 4.71% |
| net income growth | 44.44% | 28.46% | 24% | 120% |
| revenue growth | 19.16% | 17.07% | 21% | 27% |
| roce | — | -4.42% | -4.82% | 15.13% |
| roe | — | -11.63% | 29.38% | — |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 84 | 76 | 81 | 100 | 102 | 95 | 100 | 117 | 118 | 116 | 120 | 143 |
| Expenses | 61 | 55 | 56 | 69 | 72 | 69 | 68 | 80 | 78 | 82 | 86 | 100 |
| Operating Profit | 23 | 21 | 24 | 31 | 30 | 26 | 32 | 37 | 40 | 34 | 34 | 43 |
| OPM % | 28 | 27 | 30 | 31 | 29 | 27 | 32 | 32 | 34 | 30 | 28 | 30 |
| Other Income | 1 | 1 | 2 | 0 | 2 | 2 | 0 | 1 | 1 | 3 | 2 | 2 |
| Interest | 2 | 2 | 2 | 3 | 4 | 4 | 3 | 4 | 4 | 2 | 2 | 3 |
| Depreciation | 6 | 7 | 8 | 10 | 9 | 10 | 10 | 11 | 11 | 12 | 12 | 11 |
| Profit before tax | 17 | 13 | 17 | 19 | 19 | 14 | 19 | 23 | 26 | 23 | 21 | 31 |
| Tax % | 24 | 26 | 26 | 25 | 26 | 26 | 14 | 26 | 25 | 26 | 24 | 24 |
| Net Profit | 13 | 9 | 13 | 14 | 14 | 10 | 16 | 17 | 19 | 17 | 16 | 23 |
| EPS in Rs | 26.79 | 20.09 | 27.21 | 30.02 | 30.11 | 22.13 | 34.02 | 36.72 | 39.98 | 35.76 | 33.6 | 48.38 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 153 | 170 | 176 | 140 | 201 | 268 | 319 | 397 | 471 | 497 |
| Expenses | 129 | 140 | 129 | 109 | 143 | 192 | 227 | 277 | 326 | 345 |
| Operating Profit | 24 | 30 | 47 | 31 | 59 | 76 | 92 | 120 | 145 | 151 |
| OPM % | 16 | 18 | 27 | 22 | 29 | 28 | 29 | 30 | 31 | 30 |
| Other Income | 2 | 2 | 3 | 1 | 1 | 2 | 5 | 5 | 6 | 7 |
| Interest | 3 | 4 | 9 | 7 | 7 | 8 | 8 | 15 | 12 | 10 |
| Depreciation | 10 | 11 | 21 | 19 | 20 | 20 | 27 | 39 | 46 | 47 |
| Profit before tax | 13 | 17 | 20 | 6 | 32 | 49 | 62 | 71 | 94 | 101 |
| Tax % | 49 | 32 | 31 | 125 | 25 | 25 | 26 | 23 | 25 | — |
| Net Profit | 7 | 12 | 14 | -1 | 24 | 37 | 46 | 55 | 70 | 76 |
| EPS in Rs | 14.43 | 25.36 | 29.11 | -3.06 | 51.28 | 78.55 | 98.64 | 116.28 | 145.05 | 157.72 |
| Dividend Payout % | 8 | 6 | 0 | 0 | 6 | 4 | 3 | 5 | 3 | — |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Equity Capital | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| Reserves | 25 | 30 | 41 | 51 | 50 | 73 | 109 | 152 | 205 | 341 |
| Borrowings | 23 | 18 | 24 | 60 | 68 | 193 | 232 | 268 | 333 | 326 |
| Other Liabilities | 20 | 28 | 31 | 24 | 33 | 42 | 44 | 71 | 71 | 94 |
| Total Liabilities | 72 | 81 | 100 | 141 | 155 | 314 | 390 | 496 | 613 | 766 |
| Fixed Assets | 33 | 36 | 55 | 94 | 96 | 214 | 260 | 316 | 393 | 403 |
| CWIP | 1 | 3 | 0 | 0 | 0 | 26 | 62 | 97 | 128 | 197 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 13 | 89 |
| Other Assets | 38 | 42 | 45 | 47 | 60 | 73 | 67 | 83 | 80 | 78 |
| Total Assets | 72 | 81 | 100 | 141 | 155 | 314 | 390 | 496 | 613 | 766 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | 20 | 19 | 25 | 39 | 34 | 57 | 70 | 90 | 94 | 145 |
| Cash from Investing Activity | -8 | -11 | -25 | -17 | -11 | -46 | -71 | -70 | -133 | -174 |
| Cash from Financing Activity | -12 | -8 | 2 | -20 | -8 | -4 | 0 | -14 | 17 | 25 |
| Net Cash Flow | 0 | 0 | 2 | 2 | 15 | 7 | -1 | 6 | -22 | -4 |
| Free Cash Flow | 12 | 7 | 0 | 22 | 23 | 10 | -1 | 19 | -8 | 47 |
| CFO/OP | 103 | 98 | 111 | 96 | 120 | 112 | 107 | 112 | 95 | 106 |

### Ratios

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Debtor Days | 16 | 17 | 19 | 14 | 23 | 16 | 14 | 15 | 13 | 14 |
| Inventory Days | 123 | 148 | 124 | 132 | 117 | 91 | 73 | 106 | 117 | 109 |
| Days Payable | 277 | 353 | 292 | 224 | 401 | 410 | 327 | 345 | 263 | 208 |
| Cash Conversion Cycle | -138 | -189 | -149 | -78 | -260 | -303 | -240 | -224 | -133 | -84 |
| Working Capital Days | -25 | -39 | -22 | -34 | -70 | -58 | -50 | -63 | -51 | 14 |
| ROCE % | 29 | 32 | 34 | 30 | 11 | 20 | 19 | 18 | 18 | 17 |

## Shareholding Pattern

### Quarterly

| Category | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Promoters | 71.9% | 71.9% | 71.9% | 71.9% | 71.9% | 71.9% | 71.9% | 71.9% | 72.67% | 72.67% | 72.67% | 72.67% |
| FIIs | 0.28% | 0% | 0.64% | 0.65% | 0.83% | 0.84% | 1.33% | 1.5% | 1.74% | 1.82% | 2.2% | 2.24% |
| DIIs | 0% | 0% | 0% | 0% | 0.96% | 1.03% | 1.95% | 2.31% | 2.36% | 2.36% | 2.12% | 2.05% |
| Government | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Public | 22.15% | 21.84% | 21.74% | 21.77% | 20.51% | 20.44% | 19.25% | 18.95% | 18.17% | 17.96% | 17.93% | 18.01% |
| Others | 5.67% | 6.27% | 5.72% | 5.69% | 5.8% | 5.79% | 5.57% | 5.34% | 5.06% | 5.19% | 5.07% | 5.03% |
| No. of Shareholders | 3471 | 3423 | 3572 | 3808 | 4510 | 15115 | 41704 | 35976 | 30528 | 25449 | 24036 | 22954 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Strong Buy
- **Buy / Neutral / Sell:** 10 / 6 / 3

### Moving Averages — summary: **Strong Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 5320.2 | Sell |
| EMA (10) | 5305.96 | Buy |
| SMA (20) | 5310.83 | Sell |
| EMA (20) | 5293.3 | Buy |
| SMA (50) | 5179.13 | Buy |
| EMA (50) | 5214.03 | Buy |
| SMA (100) | 5108.53 | Buy |
| EMA (100) | 5125.1 | Buy |
| SMA (200) | 5042.59 | Buy |
| EMA (200) | 4997.2 | Buy |

### Oscillators — summary: **Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 52.21 | Neutral |
| MACD (12,26,9) | 27.65 | Sell |
| Stochastic (14,3,3) | 38.3 | Neutral |
| ADX (14) | 31.75 | Buy |
| Williams %R (14) | -55.44 | Neutral |
| ATR (14) | 143.81 | Neutral |
| ROC (12) | 1.15 | Buy |
| Stoch RSI (14) | 38.37 | Neutral |
| UO (7,14,28) | 41.51 | Neutral |

## Analyst Ratings

| Recommendation | Analysts | Share |
| --- | --- | --- |
| Buy | 1 | 100% |
| Hold | 0 | 0% |
| Sell | 0 | 0% |

Based on 1 analyst ratings, observed at 2026-09-11T04:53:41.359144+00:00.

## Filings & Documents

### Exchange Filings & Announcements

| Date | Document |
| --- | --- |
| 2026-09-10 | [Shareholder Meeting / Postal Ballot-Scrutinizers Report](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4003ac59-8ef8-4945-a394-817db47c31a8.pdf) |
| 2026-09-09 | [Shareholder Meeting / Postal Ballot-Outcome of AGM](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=46089ae6-d742-458b-8066-29ca579245c1.pdf) |
| 2026-08-27 | [Announcement under Regulation 30 (LODR)-Press Release / Media Release](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e356c3aa-5cf8-4f22-b2a2-f4c9e22fd474.pdf) |
| 2026-08-15 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=faca2ad7-8cd8-45ad-8e85-efe738f0e798.pdf) |
| 2026-08-14 | [Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6AF3B446_1271_4F04_B575_37AA65D6415E_110119.pdf) |
| 2026-08-14 | [Reg. 34 (1) Annual Report.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a78c445a-5f1b-403f-a3b2-825b55b37aa3.pdf) |
| 2026-08-14 | [Intimation Of Record Date Under Regulation 42 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=fb6ab0af-e2fb-42ce-9f27-48318510d0e0.pdf) |
| 2026-08-14 | [32Nd Annual General Meeting Of The Members Of The Company- September 09 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=80d88bac-4973-4719-9bd6-9c26965bfff8.pdf) |
| 2026-08-03 | [Board Meeting Outcome for Outcome Of The Board Meeting Held On August 03 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=193a00f9-e8ad-4f47-851f-aa6a8aba74e2.pdf) |
| 2026-08-03 | [Announcement under Regulation 30 (LODR)-Change in Management](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d1ed69ac-f45c-4e64-8bc3-091fc31e5c43.pdf) |

### Results & Financial Statements

| Date | Document |
| --- | --- |
| 2026-08-03 | [Results- Unaudited Financial Results For The Quarter Ended June 30 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1516ee9b-ce90-417d-8e05-ae85a5fbf01e.pdf) |
| 2026-05-20 | [Audited Financial Results Of The Company For The Quarter And Year Ended March 31 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8de24049-216a-4e69-95ad-86c9c21b8a22.pdf) |
| 2026-02-03 | [Results- Financial Results For The Quarter And Nine Months Ended December 31 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=25c12b95-7ec7-4b4b-b9f3-aa9c9a80e01e.pdf) |
| 2025-10-30 | [Unaudited Financial Results For The Quarter And Half Year Ended September 30 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2224b5fe-110a-4518-9021-3c11feaf7699.pdf) |
| 2025-08-12 | [Results- Financial Results For June 30 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=34f683d8-26b9-4852-a1a7-04d7535b800a.pdf) |
| 2025-05-28 | [Audited Results-31-03-2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=45011e81-1924-435a-a330-0a90d75576d7.pdf) |
| 2025-02-14 | [Results- Financial Results For The Quarter And Nine Months Ended 31-12-2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5c57b72d-6266-480c-a840-a3af8b517c97.pdf) |
| 2024-10-29 | [Results- Financial Results For The Quarter And 6 Months Ended 30.09.2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=43a15ead-ec09-4b3e-be71-a4a532227374.pdf) |
| 2024-07-25 | [Results-Financial Results For The Quarter Ended June 30, 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7971df72-738b-4782-885a-1089f8a8daa3.pdf) |
| 2024-04-25 | [Results- Financial Results For The Quarter And Year Ended March 31, 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=82c39bad-78ac-451f-8d96-fdcb9cb3210b.pdf) |

### Other Documents

| Date | Document |
| --- | --- |
| 9h - NCLT allowed meetings for AEHL-AHCL amalgamation scheme on July 2, 2026. | [Receipt Of Order Passed By The Hon'Ble NCLT, In Relation To The Scheme Of Amalgamation Between Dr. Agarwal'S Eye Hospital Limited And Dr. Agarwal'S Health Care Limited 9h - NCLT allowed meetings for AEHL-AHCL amalgamation scheme on July 2, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/2740236a-c318-43a3-a24d-41d7c48c4b25.pdf) |
| 9 Feb - Board meeting on 14 Feb 2026 to approve Q3 and nine-month unaudited results ended 31 Dec 2025. | [Board Meeting Intimation for Consider And Approve The Standalone & Consolidated Financial Statement For The Quarter And Nine Months Ended On 31.12.2025 9 Feb - Board meeting on 14 Feb 2026 to approve Q3 and nine-month unaudited results ended 31 Dec 2025.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/51075bce-f1f6-4a6e-8356-90de411852a8.pdf) |
| 7 Apr - Disclosure under Regulation 74(5) of SEBI (DP) Regulations is submitted. | [Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 7 Apr - Disclosure under Regulation 74(5) of SEBI (DP) Regulations is submitted.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/7a15f20a-4651-4850-a3cd-ac3825d81e65.pdf) |
| 3 Mar - IVR BBB-/stable for Rs97.49Cr and IVR A3 for Rs16.48Cr; received 02-Mar-2026. | [Announcement under Regulation 30 (LODR)-Credit Rating 3 Mar - IVR BBB-/stable for Rs97.49Cr and IVR A3 for Rs16.48Cr; received 02-Mar-2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/eaaf821c-8891-4df6-b68e-39f9970f2da1.pdf) |
| 3 Feb - Unaudited Q3/9M results: 9M profit ₹53.86Cr; registered office shift effective Feb 05, 2026. | [Board Meeting Outcome for Unaudited Financial Results For The Quarter And Nine Months Ended December 31, 2025 3 Feb - Unaudited Q3/9M results: 9M profit ₹53.86Cr; registered office shift effective Feb 05, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/fe97ed06-3509-44b4-8544-f710323a6f0f.pdf) |
| 3 Feb - Unaudited Q3/9M FY26 results: 9M revenue Rs350.9cr, PAT Rs53.9cr; registered office shifted Feb 5, 2026. | [Announcement under Regulation 30 (LODR)-Change in Registered Office Address 3 Feb - Unaudited Q3/9M FY26 results: 9M revenue Rs350.9cr, PAT Rs53.9cr; registered office shifted Feb 5, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/c2f5b20b-0946-42d1-8873-8affa247b5cb.pdf) |
| 3 Feb - Approved unaudited results to Dec 31, 2025; registered office shifted effective Feb 05, 2026. | [Results- Financial Results For The Quarter And Nine Months Ended December 31, 2025 3 Feb - Approved unaudited results to Dec 31, 2025; registered office shifted effective Feb 05, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/25c12b95-7ec7-4b4b-b9f3-aa9c9a80e01e.pdf) |
| 28 Jan - Board meeting Feb 03, 2026 approves unaudited results quarter and nine months ended Dec 31, 2025; trading window closed. | [Board Meeting Intimation for Consideration And Approval Of Unaudited Financial Results For The Quarter And Nine Months Ended December 31, 2025 28 Jan - Board meeting Feb 03, 2026 approves unaudited results quarter and nine months ended Dec 31, 2025; trading window closed.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/d3eac15d-4a74-41a7-8523-27cf09159f56.pdf) |
| 23 Feb - Feb 23, 2026: ICRA assigned ICRA AA- (Stable) to ₹85.80Cr loan; AA-/A1+ to ₹54.20Cr limits. | [Announcement under Regulation 30 (LODR)-Credit Rating 23 Feb - Feb 23, 2026: ICRA assigned ICRA AA- (Stable) to ₹85.80Cr loan; AA-/A1+ to ₹54.20Cr limits.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/9591ac8c-5da5-4c55-b3ee-8949bcf412df.pdf) |
| 21 Apr - Dr Agarwal’s Eye Hospital shares admitted to trade on NSE from April 20, 2026, symbol DRAGARWQ. | [Trading And Admission To Dealings Of The Company'S Equity Shares On The National Stock Exchange Of India Limited 21 Apr - Dr Agarwal’s Eye Hospital shares admitted to trade on NSE from April 20, 2026, symbol DRAGARWQ.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/36e4d595-3a0f-4788-b351-f99f1f729b5b.pdf) |

### Investor Presentations

| Date | Document |
| --- | --- |
| 2025-08-27 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=cbeb56e1-6e78-4812-9c74-17ca75af0165.pdf) |

### Earnings Call Documents

| Date | Document |
| --- | --- |
| Oct 2021 | [Concall - Oct 2021](https://www.bseindia.com/xml-data/corpfiling/AttachHis/ca64a271-a362-43b9-94a3-11d47d08776a.pdf) |
| Nov 2023 | [Concall - Nov 2023](https://www.bseindia.com/xml-data/corpfiling/AttachHis/b5645389-3841-4353-a244-0a075013cc7c.pdf) |
| Nov 2022 | [Concall - Nov 2022](https://www.bseindia.com/xml-data/corpfiling/AttachHis/a36bde88-c43a-4b81-946e-3399b4d8998b.pdf) |
| May 2023 | [Concall - May 2023](https://www.bseindia.com/xml-data/corpfiling/AttachHis/e725ce8b-d9ce-49a0-a3ef-e9f847a60454.pdf) |
| May 2023 | [Concall - May 2023](https://www.bseindia.com/xml-data/corpfiling/AttachHis/80028f67-0ae9-4019-8c65-3d706f4cda76.pdf) |
| Jan 2022 | [Concall - Jan 2022](https://www.bseindia.com/xml-data/corpfiling/AttachHis/f20e636a-b56e-4808-9c0b-f98f5f4d0427.pdf) |
| Feb 2023 | [Concall - Feb 2023](https://www.bseindia.com/xml-data/corpfiling/AttachHis/00ed6d67-2281-4829-b362-78aea5686e76.pdf) |
| Aug 2025 | [Concall - Aug 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/cbeb56e1-6e78-4812-9c74-17ca75af0165.pdf) |
| Aug 2022 | [Concall - Aug 2022](https://www.bseindia.com/xml-data/corpfiling/AttachHis/ac9fd24f-a35e-419c-9285-e8d598bbfbbd.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from nse | [Financial Year 2022 from nse](https://archives.nseindia.com/annual_reports/AR_20683_EXXARO_2021_2022_10082022184004_08102022190002.zip) |
| from bse | [Financial Year 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/7362c738-45eb-42de-9542-5df0769390ef.pdf) |
| from bse | [Annual Report 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/346a7fbc-6d5d-42cd-8800-5bb9ffbb07e7.pdf) |
| from bse | [Financial Year 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/8b85361f-686b-4f40-a631-78eaa4ccac5e.pdf) |
| from bse | [Annual Report 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/0ba2052f-5942-4b74-a0b6-6ee83cbfab06.pdf) |
| from bse | [Financial Year 2023 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/9cff461d-eaba-4203-8b21-c8b4c0dd6e9e.pdf) |
| from bse | [Annual Report 2023 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/2daf0c3c-f95b-48ea-9487-fa5d544f79a4.pdf) |
| from bse | [Financial Year 2022 from bse](https://www.bseindia.com/bseplus/AnnualReport/543327/74256543327.pdf) |
| from bse | [Annual Report 2022 from bse](https://www.bseindia.com/bseplus/AnnualReport/526783/74569526783.pdf) |
| from bse | [Annual Report 2021 from bse](https://www.bseindia.com/bseplus/AnnualReport/526783/72044526783.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T19:16:01.643Z.